Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Restructuring and acquisition-related costs: 10.71M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Financial Fact:
Restructuring and acquisition-related costs: 10.71M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.99, versus $0.02 reported in the same period last year.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.45-$4.70, versus prior guidance of $3.95-$4.20. Valeant Pharmaceuticals International, Inc. sees FY2012 revenue of $3.4-$3.6 billion.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.45-$4.70, versus prior guidance of $3.95-$4.20. Valeant Pharmaceuticals International, Inc. sees FY2012 revenue of $3.4-$3.6 billion.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
- GitLab’s second-quarter revenue jumps 21% as AI demand drives bookings
- UBS Upgrades Zhejiang Leapmotor Technology (9863:HK) to Buy
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
